Active Not Recruiting PHASE1 INTERVENTIONAL 3-arm NCT06415461

A Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ) (SIJ)

A Phase 1, Open Label Dose-Ranging Study to Assess the Safety, Tolerability, Preliminary Efficacy, and Dose Effect of CFL001 Cord Blood Product in Patients With Symptomatic Sacroiliac Joint Syndrome

Sponsor: Cord for Life, Inc.

Conditions Pain, Back Sacroiliac; Backache

Interventions PremierMaxCB®-Platinum (CFL001);

Updated 6 times since 2024 Last updated: Jan 15, 2026 Started: May 10, 2024 Primary completion: Jan 15, 2027 Completion: Mar 6, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pain, Back and Sacroiliac; Backache and is currently ongoing. Cord for Life, Inc. leads this study, which shows 6 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Aug 2025 — Feb 2026 [monthly]

Recruiting PHASE1
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Jul 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

May 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cord for Life, Inc.
University of Florida

Data source: University of Florida

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gainesville, United States